Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme and Vertex sign deal for Hypercon technology
Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics,
Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics,
The funding will be used for commercial readiness and the potential US launch of the company’s lead product candidate, AD109, pending approval by the US Food and Drug
The transaction will expand Neurocrine’s portfolio in endocrinology and rare diseases via the addition of Soleno’s lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR
The project will enhance Aspect Biosystems’ clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the
The approval in the European Union (EU) is for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours are PD-L1 positive, with a combined
This follows the company’s signing of a definitive agreement in October 2025 to acquire the business. The deal adds advanced Protein A chromatography capabilities and Amsphere Protein A
Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation. The collaboration will focus on advanced
The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial
The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. Molecular glues are an emerging therapeutic modality
The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved